▲ BUY
5
/ 10
Conviction
$ Value
—
Shares
889,865
Price
—
Filed
Nov 18
▶ Why this score? (5/10)
- ✓ Open market buy (+3)
- ✓ 10%+ owner (+1)
- ✓ Not a 10b5-1 plan (+1)
Insider
Name
PharmaCyte Biotech, Inc.
Title
—
CIK
0001157075
Roles
10% Owner
Transaction Details
Transaction Date
2025-11-14
Code
P
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
889,865
Footnotes
The Series H Convertible Preferred Stock is convertible into shares of common stock at a conversion price of $3.3713, subject to adjustment. The Series H Convertible Preferred Stock and warrants became convertible upon shareholder approval for the issuance of the underlying common stock at a special meeting held on November 14, 2025. The conversion rights of the Series H Convertible Preferred Stock do not expire.
Filing Info
Other Insiders at QCLS (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Silverman Joshua
Executive Chairman
|
— | — | 2026-04-13 |
| White Billy Joe | — | — | 2026-04-13 |
| Bernstein Bruce | — | — | 2026-04-13 |
|
Glass Mitchell
Chief Medical Officer
|
— | — | 2026-04-13 |
| Friscia Stephen | — | — | 2026-04-13 |
| Voss Chelsea Sierra | — | — | 2026-04-13 |